XellSmart Unveils Positive Phase 1 Results for Off-the-Shelf Parkinson's Disease Cell Therapy and Completes Phase 2 Enrollment

XellSmart presented landmark Phase 1 clinical trial results for its off-the-shelf cell therapy, XS411, for Parkinson's Disease at the International Congress of Parkinson's Disease and Movement Disorders (MDS). The trial, involving nine participants, met its primary safety and tolerability objectives, showing sustained improvements in motor function and quality of life. Gold-standard ¹⁸F-DOPA PET imaging confirmed increased cerebral dopamine synthesis. XellSmart also announced the full enrollment of its multicenter, randomized, parallel-group Phase 2 trial in China.